B
Barbara J. Gitlitz
Researcher at Genentech
Publications - 3
Citations - 536
Barbara J. Gitlitz is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Lung cancer. The author has an hindex of 2, co-authored 3 publications receiving 25 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Enriqueta Felip,Nasser K. Altorki,Caicun Zhou,Tibor Csőszi,Ihor Vynnychenko,Oleksandr Goloborodko,Alexander Luft,Andrey Akopov,Alex Martinez-Marti,Hirotsugu Kenmotsu,Yuh-Min Chen,Antonio Chella,Shunichi Sugawara,David Voong,Fan Wu,Jing Yi,Yu Deng,Mark McCleland,Elizabeth Bennett,Barbara J. Gitlitz,Heather A. Wakelee,IMpower Investigators +21 more
TL;DR: The IMpower010 trial as mentioned in this paper evaluated adjuvant atezolizumab versus best supportive care (observation and regular scans for disease recurrence) in patients with early-stage non-small-cell lung cancer.
Journal ArticleDOI
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Heather A. Wakelee,Nasser K. Altorki,Caicun Zhou,Tibor Csőszi,Ihor Vynnychenko,Oleksandr Goloborodko,Alexander Luft,Andrey Akopov,Alex Martinez-Marti,Hirotsugu Kenmotsu,Yuh Min Chen,Antonio Chella,Shunichi Sugawara,Barbara J. Gitlitz,Elizabeth Bennett,Fan Wu,Jing Yi,Yu Deng,Mark McCleland,Enriqueta Felip +19 more
TL;DR: Adjuvant platinum-based chemotherapy provides only a modest 5-year survival benefit in fully resected, high-risk early-stage NSCLC and the primary disease-free survival benefit is reported.
Journal ArticleDOI
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC.
Jay M. Lee,Anthony W. Kim,Tomasz Marjański,Pierre-Emmanuel Falcoz,Masahiro Tsuboi,Yi-Long Wu,Shawn W. Sun,Barbara J. Gitlitz +7 more
TL;DR: The standardization, reporting, and prospective inclusion of these end points in study protocols would provide a comparative overview of the impact of different neoadjuvant immunotherapy regimens on surgery and ultimately clinical oncologic outcomes in resectable NSCLC.